A5070919285- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Poisoning and overdose treatments
- Antimicrobial Resistance in Staphylococcus
- Autoimmune Bullous Skin Diseases
- Bacterial Identification and Susceptibility Testing
- Transplantation: Methods and Outcomes
- Platelet Disorders and Treatments
- Infections and bacterial resistance
- Blood disorders and treatments
- Bacterial biofilms and quorum sensing
- Pharmacovigilance and Adverse Drug Reactions
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Hormonal Regulation and Hypertension
- Neurological Complications and Syndromes
- Acute Kidney Injury Research
- Cardiac Structural Anomalies and Repair
- Neutropenia and Cancer Infections
- Urinary Tract Infections Management
- Mechanical Circulatory Support Devices
- Antifungal resistance and susceptibility
- Electrolyte and hormonal disorders
University of Houston
2023-2025
St. Luke's Hospital
2022-2025
Cefiderocol is a siderophore cephalosporin designed to target multi-drug-resistant Gram-negative bacteria. Previously, the emergence of cefiderocol non-susceptibility has been associated with mutations in chromosomal cephalosporinase (PDC) along PirA and PiuA/D TonB-dependent receptor pathways. Here, we report clinical case cefiderocol-resistant
Vancomycin ranks amongst the most utilized antimicrobial agents in treatment of serious β-lactam-resistant Gram-positive infections, but its use has been associated with nephrotoxicity. Reduction acute kidney injury (AKI) reported pre-clinical models adjuvant montelukast. The purpose study was to ascertain if montelukast a reduction prevalence vancomycin-associated AKI. In this retrospective cohort study, adult patients who received intravenous vancomycin between January 2020 2024 were...
Abstract Background Vancomycin is the most common antimicrobial used for treatment of serious infections implicated by β-lactam resistant Gram-positive bacteria but has been associated with acute kidney injury (AKI) in up to 43% cases. Reduction renal nephrotoxins reported an animal model adjuvant montelukast. However, it unclear if this protective effect could be translated improve patient outcomes. The objective study was ascertain montelukast correlated reduced vancomycin-associated AKI....
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a global concern as effective treatments are very limited. We previously used modified susceptibility testing approach to predict growth suppression in carbapenem-resistant Enterobacterales, but there uncertainties about the generalizability of model. The objective this study verify if similar can be extended CRAB.
Acute myeloid (AML) and promyelocytic (APL) leukemia patients are at high risk for infection mortality. While guidance prevention is provided by the National Comprehensive Cancer Network (NCCN) American Society of Clinical Oncology (ASCO), each institution may vary in antimicrobial prophylaxis prescribing practices. The discrepancy be explained medication intolerance, cost, low incidence mold infections patients. A recent meta-analysis demonstrated mortality benefits with use posaconazole,...
Abstract Background Stenotrophomonas maltophilia can cause nosocomial infections in immunocompromised hosts and patients with indwelling devices or broad-spectrum antibiotic exposure. Treatment of S poses a challenge due to intrinsic resistance mechanisms, including inducible L1 metallo L2 cephalosporinase beta-lactamases. Trimethoprim-sulfamethoxazole (SXT) is recognized as the agent choice for infections. Outcomes alternative antimicrobials are not well described. Methods We conducted...
Abstract Background Cefiderocol is a novel siderophore cephalosporin that demonstrated in vitro activity against carbapenem-resistant Enterobacterales, Acinetobacter baumannii (AB), Pseudomonas aeruginosa (PA), and Stenotrophomonas maltophilia. promising efficacy randomized, clinical trials; however, real-world utilization of cefiderocol not well characterized. Methods This was retrospective study adults who received for ≥72h serious meropenem-resistant Gram negative infections at our...
Abstract Background Ventricular assist devices (VAD) prolong life expectancy or serve as a bridge to heart transplant in end stage failure but are not without risks. These patients at high risk for device-related infections with propensity relapse. Indications and efficacy of chronic antimicrobial suppression (CAS) prevent relapse well defined. Methods We conducted retrospective study all adult VAD our institution between 1/1/2013 10/31/2020. VAD-specific VAD-related were defined by the...